Preeclampsia
Conditions
Keywords
Preeclampsia, Pregnancy, Complications, Eclampsia, Aquaporin, Aquaporin 4
Brief summary
This is a research study designed to help identify preeclampsia in pregnant women earlier, and possibly lead to better treatment for women preeclampsia.
Detailed description
There is a paucity of biomarkers to predict preeclampsia and for predicting the severity of preeclampsia. This study was designed to identify novel biomarkers for both the prediction of preeclampsia in previously normal pregnancies and for the prediction of the severity of preeclampsia in preeclamptic women. The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence and the investigators also plan testing for novel markers using various approaches such as proteomics, lipidomics and genomics. The targeted markers will include Aquaporin 4 (AQP4), soluble aquaporin fragments, chemokines, and halogenated fatty acids in the plasma and/or spinal fluid. Aquaporin fragments and AQP4 have been hypothesized to correlate with severe headaches which are complications of severe preeclampsia. The investigators found in their murine studies that there is a correlation between the presence of halogenated fatty acids in the plasma and elevated blood pressure in a murine model of preeclampsia. The approaches will complement the targeted analyses to identify novel markers that have not been predicted yet.
Interventions
OTHERWomen w/ Preeclampsia w/o Visual Disturbances or Headache
Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
OTHERWomen w/ Preeclampsia w/ Visual Disturbances or Headaches
Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
OTHERWomen w/o Preeclampsia
Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
Sponsors
University of Alabama at Birmingham
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Greater than or equal to 20 years of age * Greater than 24 weeks of gestation * Obstetrics/Anesthesia Team had decided that Combined Spinal/Epidural (CSE) or Spinal Anesthesia will be performed
Exclusion criteria
* Pre-pregnancy comorbidities: * hypertension, diabetes, or pulmonary hypertension * use of steroids, beta blockers, Ca channel antagonist, anticoagulants * cardiac or vascular conditions * severe headaches or visual disturbances * Inability to receive CSE or Spinal Anesthesia * Chorioamnionitis, fever, bronchitis, pneumonia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| S100B protein fragments in cord blood and placental samples | Between delivery and 2 hours after delivery | The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence |
| Aquaporin 4 protein fragments in cerebrospinal fluid | At the time of spinal or combined spinal/epidural anesthesia | The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence |
| S100B protein fragments in cerebrospinal fluid | At the time of spinal or combined spinal/epidural anesthesia | The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence |
| Aquaporin 4 protein fragments in cord blood and placental samples | Between delivery and 2 hours after delivery | The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence |
| Aquaporin 4 protein fragments in maternal blood plasma | Between hospital admission and prior to epidural or combined spinal/epidural anesthesia | The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence |
| S100B protein fragments in maternal blood plasma | Between hospital admission and prior to epidural or combined spinal/epidural anesthesia | The investigators plan to perform targeted testing for markers that The investigators predict based on their findings or based on available published evidence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fatty acids in cord blood and placental samples | Between immediately post-delivery and 2 hours after delivery | The investigators plan to perform targeted testing for markers that The investigators predict based on their findings or based on available published evidence |
| Fatty Acids in cerebrospinal fluid | during epidural or combined spinal/epidural anesthesia | The investigators plan to perform targeted testing for markers that The investigators predict based on their findings or based on available published evidence |
| Fatty acids in maternal blood | Between hospital admission and prior to epidural or combined spinal/epidural anesthesia | The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence |
Countries
United States
Outcome results
None listed